Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1043 | Control-EDI Wiki | 1.00 |
| drug1992 | Intervention-EDI and health coaching Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051436 | Renal Insufficiency, Chronic NIH | 0.33 |
| D007674 | Kidney Diseases NIH | 0.27 |
| D002908 | Chronic Disease NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.33 |
| HP:0000077 | Abnormality of the kidney HPO | 0.27 |
| HP:0000822 | Hypertension HPO | 0.20 |
Navigate: Correlations HPO
There is one clinical trial.
A) Comparing the % of change in each clearances of pro-, and anti-inflammatory mediators (cytokine, chemokines and complement) in the COVID-19 patients treated with CytoSorb as compared to the same patient population who do not receive blood purification treatment. B) Testing the Cytokinetic model by measuring cytokines in the blood stream and in the BAL to see if you can create a reverse gradient allowing a massive passage of leucocyte from the blood toward the infected lungs.
Description: comparing the % of change in cytokine's clearances of pro et anti -inflammatory types, as well chemokines and complement pathway between a control population and a treated population with sorbent technology.
Measure: comparing % of change in cytokine's clearances of pro et anti -inflammatory types Time: Day 1 to 5Description: Evaluation of the impact upon the survival rate at 28 and 90 days.Beside mortality, morbidity will be evaluate (free ventilatory days, ICU length of stay, shock free days , need of ECMO and secondary bacterial infections.
Measure: Evaluation of the impact upon the survival rate at 28 and 90 days. Time: Day 28 and Day 90Description: Chemokine kinetics over time and compared to the control group Chemkine kinetics between blood and lung [time frame at day 1,3 and 5]
Measure: Chemokine kinetics Time: Day 1 to 5Description: Cytokine kinetics in COVID critically ill patients over time and compared to the control group. [Time Frame: Day 1 to 5] Cytokine kinetics over time and compared to the control group. Chemkine kinetics between blood and lung [time frame at day 1,3 and 5]
Measure: Cytokine kinetics Time: Day 1 to 5Description: Complement pathway kinetics in COVID critically ill patients. [Time Frame: Day 1 to 5] Complement pathway kinetics over time and compared to the control group Complement pathway kinetics between blood and lung [time frame at day 1,3 and 5]
Measure: Complement pathway kinetics Time: Day 1 to 5Description: Evaluation of PaO2/FiO2 ratio evolution during ICU stay
Measure: PaO2/FiO2 ratio Time: Up to 90 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports